{"id":411659,"date":"2021-01-11T06:53:41","date_gmt":"2021-01-11T11:53:41","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411659"},"modified":"2021-01-11T06:53:41","modified_gmt":"2021-01-11T11:53:41","slug":"eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/","title":{"rendered":"Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns"},"content":{"rendered":"

<\/p>\n

Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns<\/b><\/p>\n

WOODCLIFF LAKE, N.J.–(BUSINESS WIRE<\/a>)–Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (\u201cEagle\u201d or the \u201cCompany\u201d) today announced that, on January 8, 2021, the United States District Court for the District of Delaware postponed the January 11, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al. due, in part, to ensure the health and safety of the trial teams in light of a COVID-19 concern. The trial is now scheduled to begin remotely starting February 1, 2021 and is expected to be concluded by February 5, 2021.<\/span><\/p>\n

About Eagle Pharmaceuticals, Inc. <\/b><\/p>\n

\nEagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients\u2019 lives. Eagle\u2019s commercialized products include RYANODEX\u00ae<\/sup>, BENDEKA\u00ae<\/sup>, BELRAPZO\u00ae<\/sup>, and its oncology and CNS\/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle\u2019s website at www.eagleus.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities law. Forward-looking statements are statements that are not historical facts. Words and phrases such as \u201canticipated,\u201d \u201cforward,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cmay,\u201d \u201cremain,\u201d \u201cpotential,\u201d \u201cprepare,\u201d \u201cexpected,\u201d \u201cbelieve,\u201d \u201cplan,\u201d \u201cnear future,\u201d \u201cbelief,\u201d \u201cguidance,\u201d and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements concerning the status and timing of pending or future litigation. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company\u2019s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: the impacts of the ongoing COVID-19 pandemic, including further disruption or delay of any pending or future litigation, and those risks and uncertainties identified in the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on March 2, 2020 as updated by its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020, filed with the SEC on May 11, 2020, August 10, 2020 and November 2, 2020, respectively, and its other subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210111005290\/en\/<\/a><\/span><\/p>\n

Investor Relations for Eagle Pharmaceuticals, Inc.:
\n<\/b>
Lisa M. Wilson
\n
In-Site Communications, Inc.
\n
T: 212-452-2793
\n
E: lwilson@insitecony.com<\/a><\/p>\n

KEYWORDS:<\/b> New Jersey United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Infectious Diseases Clinical Trials Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (\u201cEagle\u201d or the \u201cCompany\u201d) today announced that, on January 8, 2021, the United States District Court for the District of Delaware postponed the January 11, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al. due, in part, to ensure the health and safety of the trial teams in light of a COVID-19 concern. The trial is now scheduled to begin remotely starting February 1, 2021 and is expected to be concluded by February 5, 2021. About Eagle Pharmaceuticals, Inc. Eagle is a fully integrated pharmaceutical … <\/p>\n

Continue reading “Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411659","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (\u201cEagle\u201d or the \u201cCompany\u201d) today announced that, on January 8, 2021, the United States District Court for the District of Delaware postponed the January 11, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al. due, in part, to ensure the health and safety of the trial teams in light of a COVID-19 concern. The trial is now scheduled to begin remotely starting February 1, 2021 and is expected to be concluded by February 5, 2021. About Eagle Pharmaceuticals, Inc. Eagle is a fully integrated pharmaceutical … Continue reading "Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T11:53:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210111005290r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns\",\"datePublished\":\"2021-01-11T11:53:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\\\/\"},\"wordCount\":532,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210111005290r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\\\/\",\"name\":\"Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210111005290r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-01-11T11:53:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210111005290r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210111005290r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/","og_locale":"en_US","og_type":"article","og_title":"Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns - Market Newsdesk","og_description":"Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (\u201cEagle\u201d or the \u201cCompany\u201d) today announced that, on January 8, 2021, the United States District Court for the District of Delaware postponed the January 11, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al. due, in part, to ensure the health and safety of the trial teams in light of a COVID-19 concern. The trial is now scheduled to begin remotely starting February 1, 2021 and is expected to be concluded by February 5, 2021. About Eagle Pharmaceuticals, Inc. Eagle is a fully integrated pharmaceutical … Continue reading \"Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T11:53:41+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210111005290r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns","datePublished":"2021-01-11T11:53:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/"},"wordCount":532,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210111005290r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/","name":"Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210111005290r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-01-11T11:53:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210111005290r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210111005290r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eagle-pharmaceuticals-announces-update-in-vasopressin-trial-trial-date-postponed-from-january-11-2021-to-february-1-2021-to-protect-against-covid-19-concerns\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411659"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411659\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}